Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - September 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (NYSE American: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 31, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022 lead plaintiff deadline.

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

NEW YORK--(BUSINESS WIRE)-- #AP013--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”), of the important October 17, 2022 lead plaintiff deadline. SO WHAT: If you purchased Ampio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMPE

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 17, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) common stock between December 29, 2020 and August 3, 2022, inclusive (the “Class Period”). If you suffered a loss on your Ampio investments or would like to inquire about pote

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. (AMPE)

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) (NYSE: AMPE) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Ampio securities between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bga

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Ampio Pharmaceuticals, Inc. (AMPE) Investors of Class Action and to Actively Participate

NEW YORK , Aug. 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022.

AMPE SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming October 17, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) common stock between December 29, 2020 and August 3, 2022, inclusive (the “Class Period”). Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to dis

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. (AMPE)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) common stock between December 29, 2020 and August 3, 2022, inclusive (the “Class Period”). Ampio investors have until October 17, 2022 to file a lead plaintiff motion. If you suffered a loss on your A

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Ampio Pharmaceuticals, Inc. (AMPE) Investors

New York, New York--(Newsfile Corp. - August 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) common stock between December 29, 2020 and August 3, 2022, inclusive (the “Class Period”). Ampio investors have until October 17, 2022 to file a lead plaintiff motion. Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Ho

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ampio Pharmaceuticals, Inc. (AMPE) Investors

New York, New York--(Newsfile Corp. - August 21, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

NEW YORK--(BUSINESS WIRE)-- #AMPE--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Ampio securities between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”). Inv

AMPIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ampio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Ampio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal s

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) investors concerning the Company's possible violations of federal securities laws. On April 20, 2022, Ampio announced that the U.S. Food and Drug Administration (“FDA”) responded negatively to its Type C meeting request for the Company's AP-013 clinical trial and that the FDA found the Company should have sought the F

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $AMPE #AMPE--Ampio Pharmaceuticals, Inc. (AMPE) is Accused of Misrepresenting the Efficacy of its Drug Ampion®

Stockholder Alert: Robbins LLP Reminds Investors it Has Filed a Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 20, 2022, Ampio announced that the U.S. Food and Drug Administration (“FDA”) responded negatively to its Type C meeting request for the Company's AP-01

The Law Offices of Frank R. Cruz Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022. SO WHAT: If you purchased Ampio Pharmaceuticals securities during the Class Period you ma

EQUITY ALERT: Rosen Law Firm Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPE

Robbins LLP Announces It Has Filed a Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc.

Applied Genetic Technologies

Alzamend Neuro

Bird Rides

Curis

DURECT

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on InvestorPlace.

6 Penny Stocks With 1,000% Upside Potential

ENGLEWOOD, Colo. , June 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders

Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of independent legal counsel.

Ampio's Independent Committee Launches Investigation Related To AP-013 Trial

ENGLEWOOD, Colo. , May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results for the first quarter ended March 31, 2022.

Ampio Pharmaceuticals Reports First-Quarter Financial Results

ENGLEWOOD, Colo. , May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio" or the "Company") today announced that an independent special committee of the Ampio Board of Directors (the "Committee"), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to, among other matters, Ampio's AP-013 clinical trial and other clinical trials.

Ampio Independent Committee to Conduct Investigation

ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced that the Company will be hosting a conference call on April 28, 2022 at 8am EDT regarding the update from the Food and Drug Administration with respect to its AP-013 study.

Ampio Pharmaceuticals, Inc. to Hold Conference Call

Harbor Custom Development, Inc.

RLX Technology

Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Ampio Pharmaceuticals Inc Stock (AMPE)